MERZ-AESTHETICS
3.6.2022 09:02:06 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base. IMCAS, held from Friday, June 3 to Sunday, June 5, 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Paris and/or virtually. Merz Aesthetics is a diamond sponsor of the global industry congress.
“This year’s IMCAS Congress is an opportunity to reunite with our partners and leading experts in dermatology, plastic surgery and aging science to bridge our respective fields and drive innovation in aesthetic medicine forward,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We exist to fuel confidence by helping people look better, feel better and live better, and we’re proud to present research across our portfolio that reinforces the need for diverse and expansive experiences for every patient.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs. As patients are starting their aesthetic journey earlier in their lives, Merz Aesthetics stands for a long term and responsible view on how patients are treated.
Merz Aesthetics is organizing a program led by esteemed medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the course of the meeting.
- Merz Aesthetics Symposium #Beautification – Embracing #Uniqueness, Advanced aesthetic strategies for the needs of diverse generations – Dr. Gabriela Casabona, Dr. Daria Voropai, Dr. Raj Aquilla, Sunday, June 5, 2022 | 10:30 – 12:30h CEST
- Merz Aesthetics support of IMCAS Cadaver Workshop with anatomist Prof. Dr. Thilo Schenck and Live Injector: Dr. Fouad Belfkira - Friday, June 3, 2022 10:30 – 11:00h CEST
- Product Analysis Session “Emerging Toxins”, Andy Curry, Assoc. Med. Director, Merz Aesthetics - Friday, June 3, 2022, 8:30 - 12:00 h CEST
- Innovation Tank, Dr. Samantha Kerr, CSO, Merz Aesthetics, Friday, June 3, 2022, 8:30 -12:00h CEST
- IMCAS Economic Tribune Round Table, Bob Rhatigan, CEO Merz Aesthetics, Saturday, June 4, 2022, 16:00 – 18:00h CEST
E-Poster Presentations
Virtual posters will be available for viewing on site for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A longitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants. Presenting author: Andy Curry , Merz Aesthetics – USA, Terrence Keaney, MD – USA, Karyn Siemasko, PhD -USA
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Presenting author: Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- A Hybrid Filler: Combining Calcium Hydroxylapatite and Hyaluronic Acid Fillers for Aesthetic Indications, Presenting author: Jonathan Kadouch , MD, PhD – Netherlands, Nabil Fakih-Gomez, MD-Lebanon.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Presenting author: Yana Yutskovskaya , MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
- Technical evaluation and comparison of calcium hydroxylapatite (CaHA) containing dermal fillers, Sarah Backfisch, Radia El-Banna, Presenting author: Cleiton Kunzler , Roland Stragies, and Nadine Hagedorn, Merz Aesthetics GmbH – Germany.
- Increased hyaluronic acid concentration enhances the local tissue lifting capacity in an ex vivo human skin model, Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.
- Animal study indicates importance of distance between microspheres for neocollagenesis, Bartosch Nowag, Nils Warfving, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 16:00:00 CET | Press release
Short film follows consumers across three countries whose stories demonstrate the power of financial inclusion, innovation and resilienceKey highlights: New Experian documentary features five individuals from the United States, Brazil and the United Kingdom whose experiences illustrate the impact of financial access and opportunity. Documentary highlights examples spanning debt relief, financial education, credit empowerment and healthcare innovation. Stories showcase how Experian's products, services and social innovation can help consumers navigate challenges and pursue personal and financial goals. For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passi
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 15:00:00 CET | Press release
FSA/HSA-Eligible Recovery Boots Deliver Five Levels of Heat and Seven Levels of Compression, Available for Pre-Order Now Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation h
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
European Commission expands license for Alfasigma’s Jyseleca® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 15:00:00 CET | Press release
Jyseleca® (filgotinib) has received expanded approval for the treatment of patients with active axial spondylarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have not responded adequately to conventional therapy. EC approval follows a positive opinion from the CHMP in September 2026 and offers a new treatment option for people living with inadequately controlled axSpA in Europe. An application has been submitted to the MHRA for UK approval and is under review. In the OLINGUITO Phase 3 study, improvements in the signs and symptoms of axSpA – including spinal pain – were observed early and maintained over 52 weeks of treatment with filgotinib. This new indication builds on previous approvals for Jyseleca® for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis in Europe and the United Kingdom. The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom